Evidence map›Paper›PMID 24772217›Full record

ArticleTranslational oncology2014

A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.

Robert L Harrison, Brian F Elston, Robert K Doot, Thomas K Lewellen, David A Mankoff, Paul E Kinahan

Abstract read
In one paragraph

Article in Translational oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. An integrated PET/CT simulation framework for virtual imaging trials and quantitative performance evaluation.Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2026
    Article
  3. A Virtual Clinical Trial to Detect Changes in Tumor Uptake with PET using Lesion Embedding.IEEE transactions on radiation and plasma medical sciences · 2026
    Article
  4. Virtual clinical trials in medical imaging: a review.Journal of medical imaging (Bellingham, Wash.) · 2020
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Robert L HarrisonDepartment of Radiology, University of Washington, Seattle, WA.
Brian F ElstonDepartment of Radiology, University of Washington, Seattle, WA.
Robert K DootDepartment of Radiology, University of Pennsylvania, Philadelphia, PA.
Thomas K LewellenDepartment of Radiology, University of Washington, Seattle, WA.
David A MankoffDepartment of Radiology, University of Pennsylvania, Philadelphia, PA.
Paul E KinahanDepartment of Radiology, University of Washington, Seattle, WA.

Funding

Advanced PET/CT Imaging for Improving Clinical TrialsU01CA148131 · NCI · UNIVERSITY OF WASHINGTON · PI KINAHAN, PAUL E., LINDEN, HANNAH M · 2010 to 2019
$6.0M
Tumor Detection &Quantitation with Emission TomographyR01CA042593 · NCI · UNIVERSITY OF WASHINGTON · PI LEWELLEN, THOMAS K · 1987 to 2016
$5.5M
Patient-specific predictive modeling that integrates advanced cancer imagingR01CA164371 · NCI · UNIVERSITY OF WASHINGTON · PI KINAHAN, PAUL E., SWANSON, KRISTIN R · 2011 to 2015
$4.5M
University of Washington Emission Tomography Simulation ResourceR01CA126593 · NCI · UNIVERSITY OF WASHINGTON · PI LEWELLEN, THOMAS K · 2007 to 2011
$1.2M
NCI NIH HHS R01 CA042593NCI NIH HHS R01 CA126593NCI NIH HHS R01 CA164371NCI NIH HHS U01 CA148131
6 · The paper itself

Abstract

introductionThere is growing interest in using positron emission tomography (PET) standardized uptake values (SUVs) to assess tumor response to therapy. However, many error sources compromise the ability to detect SUV changes. We explore relationships between these errors and overall SUV variability.

methodsWe used simulations in a virtual clinical trial framework to study impacts of error sources from scanning and analysis effects on assessment of SUV changes. We varied tumor diameter, scan duration, pretherapy SUV, magnitude of change in SUV, image reconstruction filter, and SUV metric. Poisson noise was added to the raw data before image reconstruction. Variance from global sources of error, e.g., scanner calibration, was incorporated. Two thousand independent noisy sinograms per scenario were generated and reconstructed. We used SUVs to create receiver operating characteristic (ROC) curves to quantify ability to assess response. Integrating area under the ROC curve summarized ability to detect SUV changes.

resultsScan duration and image reconstruction method had relatively little impact on ability to measure response. SUVMAX is nearly as effective as SUVMEAN, especially with increased image smoothing and despite size-matched region of interest placement. For an effective variability of 15%, we found the Positron Emission Tomography Response Criteria in Solid Tumors criteria for measuring response (±30%) similar to the European Organization for Research and Treatment of Cancer criteria (±25%).

conclusionsFor typical PET variance levels, tumor response must be 30% to 40% to be reliably determined using SUVs. PET scan duration and image reconstruction method had relatively little effect.

Identifiers

PMID24772217
PMCPMC3998682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.